Taken together, these two observations suggest that it is the delay in diagnosis using PSA‐based screening in patients with a low testosterone level that leads to a worse long‐term outcome and not necessarily a more aggressive prostate cancer biology. This evidence concerns the gene KLK3 and prostate cancer.